Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.68 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244326 | 0.95 | KCNA3 (0.76) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL22266160 | 0.94 | KCNA3 (0.60) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL26382700 | 0.93 | KCNA3 (0.73) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL21992785 | 0.93 | KCNA3 (0.73) | KCNA3HTR1BLTA4HMEN1HPGD | |
| Formaldehyde SCHEMBL27683959 | 0.89 | KCNA3 (0.67) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL19637927 | 0.88 | KCNA3 (0.54) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL19637925 | 0.88 | KCNA3 (0.54) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL213738 | 0.88 | KCNA3 (0.64) | KCNA3HTR1BLTA4HMEN1HPGD | |
| SCHEMBL1025 | 0.87 | KCNA3 (0.88) | KCNA3HTR1BLTA4HTAAR1ALDH1A1 | |
| SCHEMBL29360139 | 0.87 | LSS (0.62) | KCNA3LTA4HHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-9293711-B2 | Organic semiconductor formulations | POLYERA CORPORATION (US) | 2016-03-22 | — | — | US | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023097251-A1 | OLIGONUCLEOTIDE-CONTAINING TRANSCRIPTION FACTOR TARGETING CHIMERAS | YALE UNIVERSITY (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3904417-A1 | RESIN COMPOSITION FOR SEALING, SEMICONDUCTOR DEVICE, AND PRODUCTION METHOD FOR SEMICONDUCTOR DEVICE | Sumitomo Bakelite Co.Ltd. (JP) | 2021-11-03 | — | — | EP | disclosed |
| CN-107004768-B | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-3694856-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-08-19 | — | — | EP | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5190956-A | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections | SCHERING CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5179093-A | Viricides | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| US-5179107-A | Herpes | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1992004328-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004327-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| US-4404354-A | FROM P-DIALKOXYBENZENES, HEAT RESISTANT | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KCNA3 4718/4885HTR1B 4075/4885LTA4H 3137/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KCNA3 4796/4885HTR1B 3116/4885LTA4H 1665/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KCNA3 4718/4885HTR1B 4075/4885LTA4H 3137/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | KCNA3 2318/4885HTR1B 4496/4885LTA4H 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.